TD Asset Management Inc Cuts Stock Position in Moderna, Inc. (NASDAQ:MRNA)

TD Asset Management Inc cut its holdings in Moderna, Inc. (NASDAQ:MRNAFree Report) by 11.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 140,899 shares of the company’s stock after selling 18,692 shares during the quarter. TD Asset Management Inc’s holdings in Moderna were worth $14,012,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Quadrant Capital Group LLC boosted its stake in Moderna by 7.5% during the fourth quarter. Quadrant Capital Group LLC now owns 2,672 shares of the company’s stock worth $266,000 after buying an additional 187 shares during the period. International Assets Investment Management LLC boosted its stake in Moderna by 6,528.9% during the fourth quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock worth $38,552,000 after buying an additional 381,808 shares during the period. abrdn plc boosted its stake in shares of Moderna by 477.5% during the fourth quarter. abrdn plc now owns 483,574 shares of the company’s stock valued at $48,091,000 after purchasing an additional 399,843 shares during the period. Ontario Teachers Pension Plan Board purchased a new stake in shares of Moderna during the fourth quarter valued at $1,358,000. Finally, Van ECK Associates Corp boosted its stake in shares of Moderna by 19.2% during the fourth quarter. Van ECK Associates Corp now owns 270,774 shares of the company’s stock valued at $26,929,000 after purchasing an additional 43,646 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Stock Performance

MRNA opened at $147.82 on Tuesday. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $170.47. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04. The company has a market cap of $56.65 billion, a P/E ratio of -9.43 and a beta of 1.54. The firm’s 50-day moving average price is $121.17 and its 200-day moving average price is $104.11.

Moderna (NASDAQ:MRNAGet Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The firm had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. During the same quarter in the prior year, the company posted $0.19 earnings per share. The company’s revenue for the quarter was down 91.0% compared to the same quarter last year. As a group, equities analysts anticipate that Moderna, Inc. will post -7.47 EPS for the current fiscal year.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 544 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $99.05, for a total value of $53,883.20. Following the sale, the insider now owns 9,267 shares in the company, valued at $917,896.35. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Moderna news, CFO James M. Mock sold 648 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $162.47, for a total value of $105,280.56. Following the sale, the chief financial officer now owns 5,726 shares in the company, valued at approximately $930,303.22. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Shannon Thyme Klinger sold 544 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $99.05, for a total value of $53,883.20. Following the completion of the sale, the insider now owns 9,267 shares in the company, valued at approximately $917,896.35. The disclosure for this sale can be found here. Insiders have sold a total of 203,789 shares of company stock worth $23,868,305 over the last quarter. Insiders own 15.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Jefferies Financial Group reissued a “buy” rating and set a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Monday. Oppenheimer lifted their price objective on Moderna from $142.00 to $163.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. UBS Group lifted their price objective on Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Finally, HSBC restated a “reduce” rating and issued a $86.00 price objective (up from $75.00) on shares of Moderna in a report on Monday, February 26th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $128.02.

Check Out Our Latest Stock Analysis on MRNA

Moderna Company Profile

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

See Also

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.